

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities.

*This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities referred to herein will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), and may not be offered or sold in the United States except pursuant to an exemption from, or a transaction not subject to, the registration requirements of the Securities Act. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the company making the offer and its management and financial statements. The Company does not intend to make any public offering of securities in the United States.*



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**UPDATE ON THE SPIN-OFF AND SEPARATE LISTING OF
WUXI XDC CAYMAN INC. ON THE MAIN BOARD OF THE STOCK
EXCHANGE OF HONG KONG LIMITED**

FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

References are made to the announcements of the Company dated July 9, 2023, October 20, 2023, October 29, 2023, November 6, 2023, November 7, 2023, November 16, 2023 and November 17, 2023 (collectively, the “**Announcements**”) in relation to the Proposed Spin-off and separate listing of the SpinCo, a subsidiary of the Company, on the Main Board of the Stock Exchange. Unless otherwise specified, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus has been fully exercised by the Overall Coordinators (for themselves and on behalf of the International Underwriters) on December 8, 2023, in respect of an aggregate of 19,158,500 SpinCo Shares (the “**Over-allotment Shares**”), to facilitate the return to the Company of the 19,158,500 SpinCo Shares borrowed under the stock borrowing agreement dated November 11, 2023 which were used to cover the over-allocations in the International Offering.

The Over-allotment Shares will be issued and allotted by the SpinCo at HK\$20.60 per SpinCo Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, the Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%), being the final offer price of the SpinCo Shares under the Global Offering.

Immediately following the full exercise of the Over-allotment Option, the interest held by the Company in the total number of issued shares of the SpinCo will decrease from approximately 50.91% to approximately 50.10% (both without taking into account any exercise of the share options granted under the pre-IPO share option schemes of the SpinCo), and the SpinCo will remain as a subsidiary of the Company.

The additional net proceeds of approximately HK\$380.8 million to be received by the SpinCo from the issue and allotment of the Over-allotment Shares, after deducting the underwriting commissions and other fees and expenses payable by the SpinCo in connection with the Global Offering, will be used by the SpinCo for the purposes and in the proportions as set out in the section headed “Future Plans and Use of Proceeds” in the Prospectus.

Approval for the listing of and permission to deal in the Over-allotment Shares has already been granted by the Listing Committee of the Stock Exchange. Listing of and dealings in the Over-allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9:00 a.m. on December 13, 2023.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, December 10, 2023

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.

* *For identification purpose only*